Today: 29 April 2026
Browse Category

NASDAQ:INSM 13 August 2025 - 2 January 2026

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia shares fell about 8% Friday, closing at $31.70 after swinging between $30.76 and $34.97 on heavy volume. Options trading showed a surge in put buying, with 15,696 contracts traded, 56% above normal. The drop outpaced biotech peers as investors watched for updates on the company’s patent dispute over Yutrepia and its next earnings report, expected March 18.
2 January 2026
···
Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed shares closed Monday at $175.76, up 0.53%, then traded between $175.76 and $178.05 after hours. The stock joined the Nasdaq-100 effective Dec. 22, prompting index-related activity. No new company announcements appeared after the bell. Investors continued to weigh last week’s brensocatib CRSsNP trial failure.
23 December 2025
··
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed joined the Nasdaq-100 Index on December 22, 2025, boosting its stock visibility. Shares traded at $177.86, up 1.7%, after recent swings triggered by a failed Phase 2b trial for brensocatib in chronic rhinosinusitis, which led the company to end that program. Insmed also acquired INS1148, a Phase 2–ready monoclonal antibody, for $40 million upfront.
22 December 2025
·
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed will join the Nasdaq-100 before markets open Monday, December 22, 2025. Shares fell 11% last week after the company halted development of brensocatib in chronic rhinosinusitis without nasal polyps following a failed Phase 2b trial. The stock last traded near $174.84. Holiday trading may affect liquidity and volatility.
21 December 2025
·
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed shares closed at $174.84 Friday, rebounding 5% after a sharp drop triggered by its Phase 2b BiRCh trial failure in chronic rhinosinusitis without nasal polyps. The company discontinued development for that indication and announced the acquisition of a Phase 2–ready monoclonal antibody, INS1148, to expand its pipeline.
20 December 2025
··
Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed shares closed Friday, Dec. 19, 2025, at $174.84, up nearly 5%, after a volatile week triggered by a failed Phase 2b trial for brensocatib in CRSsNP. The company said it would discontinue that program. Shares held steady in after-hours trading. Insmed also announced the acquisition of INS1148, a Phase 2–ready monoclonal antibody.
20 December 2025
·
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed shares rose 5% to $174.90 Friday after a steep Thursday drop, following news that its Phase 2b BiRCh trial in CRSsNP missed endpoints and the program was discontinued. Trading volume spiked Thursday as shares fell 16%. The rebound came as analysts reiterated Buy ratings, citing Insmed’s bronchiectasis franchise and respiratory pipeline. The stock remains below its 52-week high of $212.75.
19 December 2025
·
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed shares fell 16% Thursday after the company said its Phase 2b trial of brensocatib in chronic rhinosinusitis without nasal polyps failed to meet endpoints, prompting it to end development for that indication. The drug’s performance matched or trailed placebo on symptom scores. Insmed reported no new safety issues. The stock traded near $166.75 after hitting a low of $158.06.
18 December 2025
···
Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

The FDA approved Insmed’s brensocatib as the first therapy for non-cystic fibrosis bronchiectasis, following positive results in a 1,700-patient trial. Novartis reported Phase 3 successes for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. In China, RemeGen’s telitacicept met its main goal in a Phase 3 Sjögren’s trial. Response Pharmaceuticals’ RDX-002 showed weight-loss maintenance in post-GLP-1 patients.
14 August 2025
···
Tech World Rocked by 8 Non‑AI Surprises This Week

Tech World Rocked by 8 Non‑AI Surprises This Week

Apple is developing a home companion robot with a 7-inch movable display and advanced Siri, targeting a 2027 launch. The FDA approved Insmed's Brinsupri as the first treatment for non-cystic fibrosis bronchiectasis, priced at $88,000 per year. ULA's Vulcan rocket completed its first operational flight, carrying Space Force payloads from Cape Canaveral. Amazon expanded Prime same-day grocery delivery to over 1,000 U.S. cities.
14 August 2025
···········
Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

The FDA approved brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis, affecting about 500,000 Americans. Novartis reported positive Phase 3 results for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. Biohaven’s OCD drug troriluzole failed in late-stage trials. Cardinal Health will acquire Solaris Health for $1.9 billion in cash.
13 August 2025
···

Stock Market Today

  • Patrick Industries Inc. (PATK) Stock Price Analysis
    April 29, 2026, 4:00 PM EDT. Patrick Industries Inc. (PATK) stock prices and returns are tracked over various multi-year periods ending March 2021. Historical performance data, covering 1 to 4 years depending on start date, highlight cumulative returns but caution that past performance does not predict future results. The data comes from Gotrade Securities Inc., a licensed trading entity regulated under Labuan Financial Services and Securities Act 2010. Investments carry risks, including capital loss, and this information is general in nature, not tailored financial advice. It is not an offer to buy or sell securities, nor intended for U.S. residents or jurisdictions where prohibited. Investors should consider their own objectives and risk tolerance.

Latest article

Vita Coco Stock Surges After COCO Earnings Beat and Coconut Water Demand Lifts 2026 Outlook

Vita Coco Stock Surges After COCO Earnings Beat and Coconut Water Demand Lifts 2026 Outlook

29 April 2026
Vita Coco shares jumped 27% Wednesday after first-quarter net sales rose 37% to $180 million, beating analyst expectations. The company raised its 2026 revenue outlook to $720–$735 million and lifted adjusted EBITDA guidance. Diluted earnings reached $0.50 per share, up from $0.31 a year earlier. Gross margin improved to 39.9% despite higher logistics and tariff costs.
Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

29 April 2026
Marathon Petroleum shares rose 3.2% to $240.05 Wednesday as investors anticipated its May 5 earnings report, following a surge in fuel margins during the first quarter. Phillips 66 and Valero also gained after posting stronger-than-expected results. Marathon’s Robinson refinery in Illinois began planned maintenance in March. U.S. gasoline prices hit $4.18 a gallon, the highest since 2022, according to AAA.
Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

29 April 2026
MaxLinear shares rose about 34% to $69.58 on Wednesday after Loop Capital upgraded the stock and raised its target to $75. The surge followed a first-quarter report showing infrastructure revenue up 136% to become the company’s largest segment. Total revenue climbed 43% to $137.2 million. MaxLinear guided second-quarter revenue to $160–$170 million, citing strong demand for data-center optical products.
Go toTop